article thumbnail

STAT+: Wyden claims Pfizer used a ‘colossal’ scheme to avoid paying billions in U.S. taxes

STAT

lawmaker described as possibly the “largest tax-dodging scheme” by a pharmaceutical company in history, Pfizer sold $20 billion in medicines to U.S. lawmaker described as possibly the “largest tax-dodging scheme” by a pharmaceutical company in history, Pfizer sold $20 billion in medicines to U.S.

article thumbnail

STAT+: Why Orexo is abandoning a digital therapeutic for depression

STAT

Swedish pharmaceutical company Orexo will no longer pursue an app for treating depression after many years of struggling to sell it. Orexo announced this week that it will no longer license the product, called Deprexis, from German manufacturer GAIA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds

STAT

In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.

article thumbnail

Grail plans FDA filing for cancer blood test after new trial

pharmaphorum

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

FDA
article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Both modalities have emerged as the most used platform technologies in developing oligonucleotide-based drugs for CNS disorders since 2020. ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51 billion) of these deals.

article thumbnail

Harnessing industry advancements to accelerate upstream process development

European Pharmaceutical Review

In recent years, leading pharmaceutical companies, such as Sanofi, successfully launched smart factory programmes. Prior to this, he began his career at Innovent Biologics in 2020 as a cell culture researcher and supervisor, responsible for leading the development of upstream process and Innovents proprietary IP in-house media.

article thumbnail

Makary: Drugs don’t have to take 10 years to get to market

pharmaphorum

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)